ISIS Pharmaceuticals filed suit against Santaris Pharma over two patents related to modified oligonucleotides and antisense modulation of beta catenin expression. 9/22, Southern District of California, 3:2011cv02214.
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
